Could good intentions lead to future danger?

The global COVID-19 pandemic has put the pharma/biopharma industry in the headlines on a daily basis. Many people compare the COVID-19 pandemic to the Spanish influenza epidemic of 1918. However, aside from their being different diseases, a major difference is the ability of the modern industry to develop and share tests and treatments with unprecedented speed.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

BIO 2020: IP’s vital role in COVID-19 fight, potential ‘chaos’ of pooling

9 June 2020 Concerns that IP is hindering the development of tools to fight the COVID-19 are unfounded, and now is the time that we need IP the most, according to big pharma representatives.

Africa

WIPO and pharma industry join forces to promote patent access

3 October 2017 The World Intellectual Property Organization (WIPO) has partnered with trade group the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) to boost access to patent information.

More on this story

Americas

BIO 2020: IP’s vital role in COVID-19 fight, potential ‘chaos’ of pooling

9 June 2020 Concerns that IP is hindering the development of tools to fight the COVID-19 are unfounded, and now is the time that we need IP the most, according to big pharma representatives.

Africa

WIPO and pharma industry join forces to promote patent access

More on this story

Americas

BIO 2020: IP’s vital role in COVID-19 fight, potential ‘chaos’ of pooling

9 June 2020 Concerns that IP is hindering the development of tools to fight the COVID-19 are unfounded, and now is the time that we need IP the most, according to big pharma representatives.

Africa

WIPO and pharma industry join forces to promote patent access